



more

03/10/04

1642\$

# TRANSMITTAL FORM

Application Serial Number	09/621,268
Filing Date	July 21, 2000
First Named Inventor	Gillies
Group Art Unit	1642
Examiner Name	K. Canella, Ph.D.
Attorney Docket No.	LEX-007

## ENCLOSURES (check all that apply)

<input checked="" type="checkbox"/> Fee Transmittal Form <input checked="" type="checkbox"/> Check Attached <input type="checkbox"/> Copy of Fee Transmittal Form	<input type="checkbox"/> Copy of Notice to File Missing Parts of Application (PTO-1553)	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment/Response <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Letter to Official Draftsperson including Drawings [Total Sheets ____]	<input type="checkbox"/> Formal Drawing(s)	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Petition Routing Slip (PTO/SB/69) and Accompanying Petition	<input type="checkbox"/> Status Letter
<input checked="" type="checkbox"/> Third Supplemental Information Disclosure Statement	<input type="checkbox"/> To Convert to a Provisional Application	<input checked="" type="checkbox"/> Return Receipt Postcard
<input checked="" type="checkbox"/> Form PTO-1449	<input type="checkbox"/> Power of Attorney (Revocation of Prior Powers)	<input type="checkbox"/> Certificate of First Class Mailing under 37 C.F.R. 1.8
<input checked="" type="checkbox"/> Copies of Third SIDS Citations (A75-A91; B105; and C180-C235)	<input type="checkbox"/> Terminal Disclaimer	<input type="checkbox"/> Additional Enclosure(s) (please identify below)
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> Executed Declaration and Power of Attorney for Utility or Design Patent Application	
<input type="checkbox"/> Response to Missing Parts/Incomplete Application	<input type="checkbox"/> Small Entity Statement	
	<input type="checkbox"/> Request for Refund	
	<input type="checkbox"/> After Allowance Communication to Group	


## CORRESPONDENCE ADDRESS

Direct all correspondence to: Patent Administrator  
Testa, Hurwitz & Thibault, LLP  
High Street Tower  
125 High Street  
Boston, MA 02110  
Tel. No.: (617) 248-7000  
Fax No.: (617) 248-7100

## SIGNATURE BLOCK

Date: March 9, 2004  
Reg. No. 48,645  
Tel. No.: (617) 248-7697  
Fax No.: (617) 248-7100

Respectfully submitted,

  
Brian A. Fairchild, Ph.D.  
Attorney for Applicant(s)  
Testa, Hurwitz & Thibault, LLP  
High Street Tower  
125 High Street  
Boston, MA 02110

# FEE TRANSMITTAL

FY 2003

MAR 09 2004

Complete if Known

Application Serial Number 09/621,268  
 Filing Date July 21, 2000  
 First Named Inventor Gillies  
 Group Art Unit 1642  
 Examiner Name K. Canella, Ph.D.  
 Attorney Docket No. LEX-007

## METHOD OF PAYMENT

1. ☒ Payment Enclosed:  
☒ Check ☐ Money Order ☐ Other
2. ☒ The Commissioner is hereby authorized to credit or charge any fee indicated below for this submission to Deposit Account No. 20-0531.  
☐ Required Fees (copy of this sheet enclosed).  
☒ Additional fee required under 37 CFR 1.16 and 1.17.  
☒ Overpayment Credit.
3. ☐ Applicant claims small entity status.

## FEE CALCULATION

### 1. FILING FEE

Large Entity Fee (\$)	Fee Description	Fee Paid
750	Utility filing fee	
330	Design filing fee	
160	Provisional filing fee	

Number Filed	Number Extra	Rate	Amount
--------------	--------------	------	--------

Total Claims - 20 = x \$ 18.00 =

Independent Claims - 3 = x \$ 84.00 =

☐ Multiple Dependent Claim(s), if any \$280.00 =

TOTAL:

SMALL ENTITY DISCOUNT:

SUBTOTAL (1) (\$) 0.00

### 2. AMENDMENT CLAIM FEES

Claims Remaining After Amend.	Highest No. Previously Paid For	Present Extra	Rate	Fee Paid
-------------------------------	---------------------------------	---------------	------	----------

Total - = x \$ 18.00 = 0.00

Indep. - = x \$ 84.00 = 0.00

☐ First Presentation of Multiple Dep. Claim + \$280.00 =

TOTAL: (\$) 0.00

SMALL ENTITY DISCOUNT: (\$) 0.00

SUBTOTAL (2) (\$) 0.00

## FEE CALCULATION (continued)

### 3. ADDITIONAL FEES

Large Entity Fee (\$)	Small Entity Fee (\$)	Fee Description	Fee Paid
130	65	Surcharge - late filing fee or oath	
50	25	Surcharge - late provisional filing fee or cover sheet	
130	130	Non-English specification	
2,520	2,520	Request for ex parte reexamination	
110	55	Extension for reply within first month	
410	205	Extension for reply within second month	
930	465	Extension for reply within third month	
1450	725	Extension for reply within fourth month	
1970	985	Extension for reply within fifth month	
320	160	Notice of Appeal	
320	160	Filing a brief in support of an appeal	
280	140	Request for oral hearing	
130	130	Petitions to the Commissioner	
180	180	Submission of Information Disclosure Statement	180.00
750	375	Filing a submission after final rejection (37 CFR 1.129(a))	
750	375	For each additional invention to be examined (37 CFR 1.129(b))	
100	100	Certificate of Correction for applicant's error	

Other fee (Specify)

Other fee (Specify)

SUBTOTAL (3) (\$) 180.00

SUBTOTAL (1) 0.00

SUBTOTAL (2) 0.00

SUBTOTAL (3) 180.00

TOTAL (\$) 180.00

## CORRESPONDENCE ADDRESS

Direct all correspondence to:

Patent Administrator  
 Testa, Hurwitz & Thibault, LLP  
 High Street Tower-125 High Street  
 Boston, MA 02110  
 Tel. No.: (617) 248-7000  
 Fax No.: (617) 248-7100

## SIGNATURE BLOCK

Respectfully submitted,

*Brian A. Fairchild*  
 Brian A. Fairchild, Ph.D.  
 Attorney for the Applicants  
 Testa, Hurwitz & Thibault, LLP  
 High Street Tower-125 High Street  
 Boston, MA 02110

Date: March 9, 2004  
 Reg. No.: 48,645  
 Tel. No.: (617) 248-7697  
 Fax No.: (617) 248-7100

**PATENT**  
Attorney Docket No. LEX-007

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS:	Gillies <i>et al.</i>		
SERIAL NO.:	09/621,268	GROUP NO.:	1642
FILING DATE:	July 21, 2000	EXAMINER:	K. Canella, Ph.D.
TITLE:	Fc Fusion Proteins for Enhancing the Immunogenicity of Protein and Peptide Antigens		

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

### **THIRD SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Sir:

In accordance with the provisions of 37 C.F.R. 1.97 and 1.98, Applicants hereby make of record the patents and publications listed on the accompanying Form PTO-1449, and other information contained herein, for consideration by the Examiner in connection with the examination of the above-identified patent application. Copies of the patents and publications are enclosed.

## REMARKS

In accordance with the provisions of 37 C.F.R. 1.97, this statement is being filed (CHECK ONE):

- ☐ (1) within three (3) months of the **filing date** of a national application other than a continued prosecution application under 37 C.F.R. 1.53(d), or within three (3) months of the **date of entry of the national stage** as set forth in 37 C.F.R. 1.491 in an international application, or before the mailing of the **first Office action** on the merits, or before the mailing of a **first Office action** after the filing of a request for continued examination under 37 C.F.R. 1.114; or
- ☒ (2) after the period defined in (1) but before the mailing date of a **final action** or a **notice of allowance** under 37 C.F.R. 1.311, and
- ☐ the requisite Statement is below, **OR**

03/11/2004 SSNDPRA 000000038 08C1269S 180.00 DP

☒ the requisite fee under 37 C.F.R. 1.17(p), namely **\$180.00**, is included herein, or

☐ (3) after the mailing date of a **final action** or **notice of allowance** but before the payment of the **issue fee**, **AND**


☐ the requisite Statement is below, **AND**

☐ the requisite petition fee under 37 C.F.R. 1.17(p), namely **\$180.00** is included herein.

It is respectfully requested that each of the patents and publications listed on the attached Form PTO-1449, and other information contained herein, be made of record in this application.

Applicants believe no additional fee is required for entry and consideration of this paper. If an additional fee is required, please charge Deposit Account 20-0531.


Respectfully submitted,



Brian A. Fairchild, Ph.D.  
Attorney for Applicants  
Testa, Hurwitz & Thibeault, LLP  
125 High Street  
Boston, Massachusetts 02110

Date: March 9, 2004  
Reg. No. 48,645  
Tel. No.: (617) 248-7697  
Fax No.: (617) 248-7100

FORM PTO - 1449

THIRD SUPPLEMENTAL INFORMATION  
DISCLOSURE STATEMENT

ATTORNEY DOCKET NO.: LEX-007

APPLICANT(S): Gillies *et al.*

SERIAL NO.: 09/621,268

FILING DATE: July 21, 2000 GROUP: 1642

## U.S. PATENT DOCUMENTS

EXAM. INIT.		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
	A75	4,703,008	10/27/87	Lin			
	A76	5,441,868	8/15/95	Lin			
	A77	5,457,038	10/10/95	Trinchieri <i>et al.</i>			
	A78	5,547,933	8/20/96	Lin			
	A79	5,618,698	4/8/97	Lin			
	A80	5,688,679	11/18/97	Powell			
	A81	5,756,349	5/26/98	Lin			
	A82	5,955,422	9/21/99	Lin			
	A83	6,231,536	5/15/01	Lentz			
	A84	6,284,536	9/4/01	Morrison <i>et al.</i>			
	A85	6,340,742	1/22/02	Burg <i>et al.</i>			
	A86	6,506,405	1/14/03	Desai <i>et al.</i>			
	A87	6,583,272	6/24/03	Bailon			
	A88	6,586,398	7/1/03	Kinstler <i>et al.</i>			
	A89	2002/0142374	10/3/02	Gallo <i>et al.</i>			
	A90	2003/0003529	1/2/03	Bayer			
	A91	2003/0012789	1/6/03	Blumberg <i>et al.</i>			

## FOREIGN PATENT DOCUMENTS

EXAM INIT.		DOCUMENT NUMBER	DATE	COUNTRY CODE	CLASS	SUB CLASS	FILING DATE	ABSTRACT ONLY	ENGLISH LANG (Y/N)
	B105	WO 00/24893	5/4/00	PCT					


EXAM. INIT. OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)


	C180	Becker <i>et al.</i> , (1996), "Long-lived and Transferable Tumor Immunity in Mice after Targeted Interleukin-2 Therapy," <i>J Clin Invest.</i> , 98(12):2801-2804.
	C181	Becker <i>et al.</i> , (1996), "T Cell-mediated Eradication of Murine Metastatic Melanoma Induced by Targeted Interleukin-2 Therapy," <i>J Exp. Med.</i> , 183(50):2361-6.
	C182	Briggs <i>et al.</i> , (1974), "Hepatic Clearance of Intact and desialylated Erythropoietin," <i>American Journal of Physiology</i> , 227(6):1385-1388.

EXAMINER

DATE CONSIDERED


FORM PTO - 1449		ATTORNEY DOCKET NO.: LEX-007	
THIRD SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT		APPLICANT(S): Gillies <i>et al.</i>	
		SERIAL NO.: 09/621,268	
		FILING DATE: July 21, 2000 GROUP: 1642	
U.S. PATENT DOCUMENTS			
EXAM. INIT.	DOCUMENT NUMBER	DATE	NAME
	C183		Chuang <i>et al.</i> , (1994), "Alteration of Lymphocyte Microtubule Assembly, Cytotoxicity, and Activation by the Anticancer Drug Taxol," <u>Cancer Research</u> , 54:1286-1291.
	C184		Cruse <i>et al.</i> , (1995), <u>Illustrated Dictionary of Immunology</u> , CRC Press, NY, p.156-7.
	C185		Davis <i>et al.</i> , (2003), "Immunocytokines: Amplification of Anti-cancer Immunity," <u>Cancer Immunol. Immunother.</u> , 52:297-308.
	C186		Dolman <i>et al.</i> , (1998), "Suppression of Human Prostate Carcinoma Metastases in Severe Combined Immunodeficient Mice by Interleukin 2 Immunocytokine Therapy," <u>Clin Cancer Res.</u> , 4(10):2551-7.
	C187		Duncan <i>et al.</i> , (1988), "The Binding Site for C1q on IgG," <u>Nature</u> , 332:738-740.
	C188		Egrie <i>et al.</i> , (2001), "Development and Characterization of Novel Erythropoiesis Stimulating Protein (NESP)," <u>Nephrol. Dial. Transplant.</u> , 16:3-13.
	C189		Elliott <i>et al.</i> , (1997), "Mapping of the Active Site of Recombinant Human Erythropoietin," <u>Blood</u> , 89(2):493-502.
	C190		Frost <i>et al.</i> , (1997), "A Phase I/II Trial of Murine Monoclonal Anti GD2 Antibody 14.G2a Plus Interleukin-2 in Children with Refractory Neuroblastoma," <u>Cancer</u> , 80:317-33.
	C191		Gan <i>et al.</i> , (1999), "Specific enzyme-linked Immunosorbent Assays for Quantitation of Antibody-cytokine Fusion Proteins," <u>Clin. Diagn. Lab. Immunol.</u> , 6(2):236-42.
	C192		Gillies <i>et al.</i> , (1991), "Expression of Genetically Engineered Immunoconjugates of Lymphotoxin and a Chimeric Anti-ganglioside GD2 Antibody," <u>Hybridoma</u> , 10(3):347-56.
	C193		Gillies <i>et al.</i> , (2002), "Bi-functional Cytokine Fusion Proteins for Gene Therapy and Antibody-targeted Treatment of Cancer," <u>Cancer Immunol. Immunother.</u> , 51(8):449-60.
	C194		Gillies <i>et al.</i> , (2002), "Improved Circulating Half-life and eEfficacy of an Antibody-interleukin 2 Immunocytokine Based on Reduced Intracellular Proteolysis," <u>Clin. Cancer Res.</u> , 8(1):210-6.
	C195		Greene <i>et al.</i> , (1975), Neuronal Properties of Hybrid Neuroblastoma X Sympathetic Ganglion Cells," <u>Proc. Natl. Acad. Sci. USA</u> , 72(12):4923-4927.
	C196		Hank <i>et al.</i> , (1996), "Activation of Human Effector Cells by a Tumor Reactive Recombinant Anti-ganglioside GD2 Interleukin-2 Fusion Protein (ch 14.18-IL2)," <u>Clin Cancer Res.</u> , 2(12):1951-9.
	C197		Hank <i>et al.</i> , (2003), "Determination of peak serum levels and immune response to the humanized anti-ganglioside antibody-interleukin-2 immunocytokine," <u>Methods Mol. Med.</u> , 85:123-31.
	C198		Haraguchi, (1994), "Isolation of GD3 Synthase Gene by Expression Cloning of GM3 $\alpha$ -2,8-sialyltransferase cDNA using anti-GD2 Monoclonal Antibody," <u>Proc. Natl. Acad. Sci. USA</u> , 91(22):10455-9.
	C199		Harris, (1995), "Processing of C-terminal Lysine and Arginine Residues of Proteins Isolated from Mammalian Cell Culture," <u>J. Chromatogr. A.</u> , 705:129-134.
	C200		Hezarah <i>et al.</i> , (2001), "Effector Function Activities of a Panel of Mutants of a Broadly Neutralizing Antibody against Human Immunodeficiency Virus Type 1," <u>J. Virol.</u> , 75(24):12161-8.
EXAMINER		DATE CONSIDERED	

FORM PTO - 1449		ATTORNEY DOCKET NO.: LEX-007					
THIRD SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT		APPLICANT(S): Gillies <i>et al.</i>					
		SERIAL NO.: 09/621,268					
		FILING DATE: July 21, 2000 GROUP: 1642					
							
EXHIBIT DOCUMENTS							
EXAM. INIT.		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
	C201	Idusogie <i>et al.</i> , (2000), "Mapping of the C1q Binding Site on Rituxan, a Chimeric Antibody with a Human IgG1 Fc," <u>J. Immunol.</u> , 164(8):4178-4184.					
	C202	Imboden <i>et al.</i> , (2001), "The Level of MHC Class I Expression on Murine Adenocarcinoma Can Change the Antitumor Effector Mechanism of Immunocytokine Therapy," <u>Cancer Res.</u> , 61(4):1500-7.					
	C203	Kato <i>et al.</i> , (1997), "Mechanism for the Nonlinear Pharmacokinetics of Erythropoietin in Rats," <u>The Journal of Pharmacology and Experimental Therapeutics</u> , 283:520-527.					
	C204	Kato <i>et al.</i> , (1998), "Pharmacokinetics of Erythropoietin in Genetically Anemic Mice," <u>Drug Metabolism and Disposition</u> , 26:126-131.					
	C205	Kushner <i>et al.</i> , (2001), "Phase II Trial of the Anti-GD2 Monoclonal-macrophage-colony-stimulating Factor for Neuroblastoma," <u>J. Clin. Oncol.</u> , 19:4189-94.					
	C206	Lode <i>et al.</i> , (1997), "Targeted interleukin-2 Therapy for Spontaneous Neuroblastoma Metastases to Bone Marrow," <u>J Natl Cancer Inst.</u> , 89(21):1586-94.					
	C207	Lode <i>et al.</i> , (2000), "What to do with Targeted IL-2," <u>Drugs Today</u> , 36(5):321-36.					
	C208	Lode <i>et al.</i> , (2000), "Melanoma Immunotherapy by Targeted IL-2 Depends on CD4(+) T-cell Help Mediated by CD40/CD40L Interaction," <u>J. Clin. Invest.</u> , 105(11):1623-30.					
	C209	Macdougall, (2002), "Optimizing the Use of Erythropoietic Agents—Pharmacokinetic and Pharmacodynamic Considerations," <u>Nephrol. Dial. Transplant.</u> , 17:66-70.					
	C210	Metelitsa <i>et al.</i> , (2002), "Antidisialoganglioside/granulocyte Macrophage-colony-stimulating Factor Ffusion Protein Facilitates Neutrophil Antibody-dependent Cellular Cytotoxicity and Depends on FcγRII (CD32) and Mac-1 (CD11b/CD18) for Enhanced Effector Cell Adhesion and Azurophil Granule Exocytosis," <u>Blood</u> , 99(11):4166-73.					
	C211	Mueller <i>et al.</i> (1997), "Humanized Porcine VCAM-specific Monoclonal Antibodies with Chimeric IgG2/G4 Constant Regions Block Human Leukocyte Binding to Porcine Endothelial Cells," <u>Molecular Immunology</u> , 34(6):441-452.					
	C212	Mullins <i>et al.</i> (1997), "Taxol-mediated Changes in Fibrosarcoma-induced Immune Cell Function: Modulation of Antitumor Activities," <u>Cancer Immunol. Immunother.</u> , 45:20-28.					
	C213	Naramura <i>et al.</i> , "Mechanisms of Cellular Cytotoxicity Mediated by a Recombinant Antibody-IL2 Fusion Protein against Human Melanoma Cells," <u>Immunology Letters</u> , 39(1):91-9.					
	C214	Neal <i>et al.</i> (2003), "NXS2 Murine Neuroblastomas Express Increased Levels of MHC Class I Antigens upon Recurrence Following NK-dependent Immunotherapy," <u>Cancer Immunol Immunother.</u> , 53:41-52.					
	C215	Ngo <i>et al.</i> , (1994), "The Protein Folding Problem and Tertiary Structure Prediction," pp. 433-440 and 492-495, Birkhauser Boston.					
	C216	Niethammer <i>et al.</i> , (2002) "An oral DNA Vaccine against Human Carcinoembryonic Antigen (CEA) Prevents Growth and Dissemination of Lewis Lung Carcinoma in CEA Transgenic Mice," <u>Vaccine</u> , 20:421-9.					
EXAMINER				DATE CONSIDERED			

FORM PTO - 1449				ATTORNEY DOCKET NO.: LEX-007			
THIRD SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT				APPLICANT(S): Gillies <i>et al.</i>			
				SERIAL NO.: 09/621,268			
				FILING DATE: July 21, 2000 GROUP: 1642			
U.S. PATENT DOCUMENTS							
EXAM. INIT.		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
	C217	Niethammer et al., (2001) "Targeted Interleukin 2 Therapy Enhances Protective Immunity Induced by an Autologous Oral DNA Vaccine against Murine Melanoma," <u>Cancer Research</u> , 61(16):6178-84.					
	C218	Nimtz et al., (1993) Structures of Sialylated Oligosaccharides of Human Erythropoietin Expressed in Recombinant BHK-21 Cells," <u>Eur. J. Biochem.</u> , 213:39-56.					
	C219	Pancook et al., (1996), "Eradication of Established Hepatic Human Neuroblastoma Metastases in Mice with Severe Combined Immunodeficiency by Antibody-targeted Interleukin-2," <u>Cancer Immunol. Immunother.</u> , 42(2):88-92.					
	C220	Park et al., (2000), "Efficiency of Promoter and Cell line in High-level Expression of Erythropoietin," <u>Biotechnol. Appl. Biochem.</u> , 32:167-172.					
	C221	Reisfeld et al., (1996), "Antibody-interleukin 2 Fusion Proteins: A New Approach to Cancer Therapy," <u>J Clin Lab Anal.</u> , 10(3):160-6.					
	C222	Reisfeld et al., (1996), "Involvement of B Lymphocytes in the Growth Inhibition of Human Pulmonary Melanoma Metastases in Athymic nu/nu Mice by an Antibody-lymphotoxin Fusion Protein," <u>Cancer Res.</u> , 56(8):1707-12.					
	C223	Ruehlmann et al., (2001), "MIG (CIXCL9) Chemokine Gene Therapy Combines with Antibody-cytokine Fusion Protein to Suppress Growth and Dissemination of Murine Colon Carcinoma," <u>Cancer Res.</u> , 61(23):8498-503.					
	C224	Sabzevari et al., (1994), "A Recombinant Antibody-interleukin 2 Fusion Protein Suppresses Growth of Hepatic Human Severe Combined Immunodeficiency Mice," <u>Proc. Natl. Acad. Sci. USA</u> , 91(20):9626-30.					
	C225	Seidenfeld et al., (2001), "Epoietin Treatment of Anemia Associated with Cancer Therapy: A Systematic Review and Meta-analysis of controlled Clinical Trials," <u>Journal of National Cancer Institute</u> , 93:1204-1214.					
	C226	Shinkawa et al., (2003), "The Absence of Fucose but Not the Presence of Galactose or Bisecting N-Acetylglucosamine of Human IgG1 Complex-type Oligosaccharides Shows the Critical Role of Enhancing Antibody-dependent Cellular Cytotoxicity," <u>J. Biol. Chem.</u> , 278:3466-3473.					
	C227	Strom et al., (1996), "Therapeutic Approach to Organ Transplantation," <u>Therapeutic Immunology</u> , Blackwell Science, Chapter 36, pp. 451-456.					
	C228	Thommesen et al., (2000), "Lysine 322 in the Human IgG3 CH2 Domain is Crucial for Antibody Dependent Complement Activation," <u>Mol. Immunol.</u> , 37(16):995-1004.					
	C229	Wells, (1990), "Additivity of Mutational Effect in Proteins," <u>Biochemistry</u> , 29(37):8509-8517.					
	C230	Xiang et al., (1998), "Induction of Persistent Tumor-protective Immunity in Mice Cured of Established Colon Carcinoma Metastases," <u>Cancer Research</u> , 58(17):3918-3925.					
	C231	Xiang et al., (1999) "T Cell Memory against Colon Carcinoma is Long-lived in the Absence of Antigen," <u>J. Immunol.</u> , 163(7):3676-83.					
	C232	Xiang et al., (2001), "A Dual Function DNA Vaccine Encoding Carcinoembryonic Antigen and CD40 Ligand Trimer induces T Cell-mediated Protective Immunity Against Colon Cancer in Carcinoembryonic Antigen-Transgenic Mice," <u>J Immunol.</u> , 167(8):4560-5.					
EXAMINER				DATE CONSIDERED			



FORM PTO - 1449

THIRD SUPPLEMENTAL INFORMATION  
DISCLOSURE STATEMENT

ATTORNEY DOCKET NO.: LEX-007

APPLICANT(S): Gillies *et al.*

SERIAL NO.: 09/621,268

FILING DATE: July 21, 2000 GROUP: 1642

## U.S. PATENT DOCUMENTS

EXAM. INIT.		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
	C233	Xiang et al., (2001), "Protective Immunity Against Human Carcinoembryonic Antigen (CEA) Induced by an Oral DNA Vaccine in CEA-transgenic Mice," <u>Clin Cancer Res.</u> , 7(3 Supp):S856-S864.					
	C234	Yu et al., (1998), "Phase I Trial of a Human-Mouse Chimeric Anti-Disialoganglioside Monoclonal Antibody ch14.18 in Patients with Refractory Neuroblastoma and Osteosarcoma," <u>J. Clin. Oncol.</u> , 16(6):2169-80.					
	C235	Zagozdzon et al. (1999), "Potentiation of Antitumor Effect of IL-12 in Combination with Paclitaxel in Murine Melanoma Model In Vivo," <u>International Journal of Molecular Medicine</u> , 4:645-648.					
EXAMINER				DATE CONSIDERED			

3030550\_1